hotspot -WSS

hotspot

author：comprehensive 2025-10-01 10:37:47 - browse：34

In a lab at Harvard Medical School, Professor David A. Sinclair looks into the camera from behind a row of bottles — coverage from STAT — David Sinclair in his lab at Harvard Medical School. Craig F. Walker/Globe Staff

Renowned Harvard University geneticist and longevity researcher David Sinclair recently made an astonishing assertion: Scientists had developed the first pill — well, a soft, beef-flavored chew — “proven to reverse aging” in dogs. Which miracle molecules delivered this supposed scientific breakthrough, he didn’t say. But he told his 438,000 followers on X where they could buy it: the website of Animal Bioscience, a veterinary supplement company he founded and which is headed by his brother, Nick Sinclair.

The claim in a company news release, followed by the tweet stating that the supplement was “proven to slow the effects of aging,” has sparked outrage from other scientists online, and the board of an international organization of top longevity researchers — which David Sinclair leads — will discuss the matter at its meeting this week.

Despite his enthusiasm, there is no published scientific research that has yet demonstrated the compounds in Animal Bioscience’s supplements — which have been on the market for more than a year — reverse or even slow aging in dogs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Most antidepressants don't work on kids, teens, study finds

focus

WSS

Novel spinal cord stimulator treats paralysis without surgery

Diversifying clinical trials isn't enough to close racial gaps: study

Has Bernie Sanders reached the limit of his pharma bullying effort?

Brain MRIs reveal impact of 'toxic stress' on Black children

FDA has safety concerns on CRISPR

Why Sanofi got shellacked over its spinoff

Wikipedia

hotspot

focus

The cancer drug shortage isn’t new — and neither are the solutions

Lawmakers grill UnitedHealth CEO on Change cyberattack

Peter Hotez and the public health issue of online harassment

The FDA weighs the risks of candy

Malaria cases in Florida and Texas: Here’s what you need to know

PBM executives asked to testify by House panel

Psychedelics group wrestles with new pharma identity

Warren pushes Witty on UnitedHealth's control over physicians

Hepatitis C has a cure — but many Americans still lack access to it

Physician subsidies by hospitals soar in wake of No Surprises Act

leisure time

AltruBio raises $225 million to develop ulcerative colitis drug

First Opinion Podcast: How to protect health care in times of war

Most antidepressants don't work on kids, teens, study finds

Eli Lilly to pay $200M for Beam’s stake in gene

Welsh Carson private equity firm escapes from FTC antitrust case

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

knowledge

leisure time

focus

hotspot